Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-03-24
2000-09-19
Davenport, Avis M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 514 15, 530324, 530325, 530326, 530327, 530328, A61K 3800, C07K 500, C07K 700, C07K 1700
Patent
active
061212369
ABSTRACT:
Disclosed are novel multivalent ligands represented by the following structural formula: ##STR1## B is a multilinker backbone. n is an integer from two to about twenty.
Each L is a covalent bond or linking group.
Each P is a peptide having from about 10 to about 30 amino acid residues. At least two of the peptides P are a peptide derivative of an AHR of an angiogenic protein, a hybrid peptide, a peptide derivative of a hybrid peptide or a combination thereof. Each peptide and each linker or covalent bond is independently chosen. The disclosed multivalent ligands can be used to modulate angiogenesis in a mammal.
Also disclosed are novel peptide derivatives of an AHR of an angiogenic protein, novel hybrid peptides, peptide derivatives of the novel hybrid peptides and polypeptide multivalent ligands thereof.
REFERENCES:
patent: 5399667 (1995-03-01), Frazier et al.
patent: 5643783 (1997-07-01), Olsen et al.
Good, D.J., et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin," Proc. Natl. Acad. Sci. USA, 87: 6624-6628, (1990).
O'Reilly, M. S. et al., "Endostatin: And Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell, 88:277-285, (1997)
Kosfeld, M. D. et al., "Identification of Active Peptide Sequences in the Carboxyl-terminal Cell Bindin Domain of Human Thrombospondin-1," The Journal of Biological Chemistry, 267:16230-16236, (1992).
Kosfeld, M. D. et al., "Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain of Human Thrombospondin," The Journal of Biological Chemistry, 268:8808-8814 (1993).
Tolsma, S.S. et al., "Peptides Drived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity," The Journal of Cell Biology, 122:497-511 (1993).
Vogel, T. et al., "Modulation of Endothelial Cell Proliferation, Adhesion, and Motility by Recombinant Heparin-Binding Domain and Synthetic Peptides from the Type 1 Repeats of Thrombospondin," Journal of Cellular Biochemistry 53:74-84 (1993).
Lin, H. B. et al., "Synthesis, surface, and cell-adhesion properties of polyurethanes containing covalently grafted RGD-peptides," Journal of Biomedical Materials Research, 28:329-342, (1994).
Tam, J. P., "Recent advances in multiple antigen peptides," Journal of Immunological Methods, 196:17-32, (1996).
Tam, J. P., "Synthetic peptide vaccine design: Synthesis properties of a high-density multiple antigenic peptide system" Proc. Natl. Acad. Sci. USA, 85:5409-5413, (1988).
Kim, W. H. et al., "Apoptosis in Human Fibrosarcoma Cells is Induced by a Multimeric Synthetic Tyr-Ile-Gly-Ser-Arg (YIGSR)-containing Polypeptide from Laminin," Cancer Research, 54:5005-5010, (1994).
Nomizu, M. et al., "Multimeric Forms of Typr-Ile-Gly-Ser-ARg (YIRGSR) Peptide Enhance the Inhibition of Tumor Growth adn Metastasis," Cancer Research, 53:3459-3461, (1994).
Folkman, J., "Angiogenisis in cancer, vascular, rheumatoid and other disease," Nature Medicine, 1:27-31 (1995).
Folkman, J., "Clinical Applications of Research on Angiogenesis," The New England Journal of Medicine, 333:1757-1763, (1995).
Roberts, D. D., "Regulation of tumor growth and metastasis by thrombospondin-1," The FASEB Journal, 10:1183-1191 (1996).
DiPietro, L. A., "Thrombospondin as a regulator of angiogenesis," In: Regulation of Angiogenesis, (eds. Goldberg, I.D., et al., ) pp. 295-314, Birkhauser Verlag, Basel/Switzerland (1997).
Bornstein, P., "Diversity of Function Is Inherent in Matricellular Proteins: An Appraisal of Thrombospondin 1," The Journal of Cell Biology, 130:503-506, (1995).
Tuszynski, G. P. et al., "The role of thrombospondin-1 in tumor progression and angiogenesis," BioEssays, 18:71-76, (1996).
Qian, X. et al., "Expression of Thrombospondin-1 in Cancer: A Role in Tumor Progression," Proc. Soc. Exp. Biol. Med., 212:199-207, (1996).
Nicosia, R. F. et al., "Matrix-Bound Thrombospondin Promotes Angiogenesis In Vitro," The Journal of Cell Biology, 124:183-193, (1994).
Hsu, S. C. et al., "Inhibition of Angiogenesis in Human Glioblastomas by Chromosome 10 Induction of Thrombospondin-1," Cancer Research 56:5684-5691, (1996).
Iruela-Arispe, M. L. et al., "Thrombospondin-1, an Inhibitor of Angiogenesis, Is Regulated by Progesterone in the Human Endometrium" J. Clin. Invest, 97:403-412, (1996).
Guo, N.H. et al., "Thrombospondin 1 and Type I Repeat Peptides of Thrombospondin 1 Specifically Induce Apoptosis of Endothelial Cells," Cancer Research 57:1735-1743, (1997).
Davenport Avis M.
The Children's Medical Center Corporation
LandOfFree
Multivalent ligands which modulate angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent ligands which modulate angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent ligands which modulate angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073272